

MCP-1 and CCR2 gene polymorphisms in Czech patients with allergic disorders

L. Izakovicova Holla,* F. Mrazek† & M. Petrek†

Summary

Several lines of evidence suggest that chemokines play an important role in asthma and allergy. We analysed polymorphisms at -2518A/G and -2076A/T of MCP-1 and V64I of CCR2 gene in healthy subjects ($n = 306$) and allergic patients ($n = 332$). Allele and genotype frequencies did not differ significantly between groups. Nevertheless, MCP-1 variants were associated with allergen sensitization. The results suggest that MCP-1, but not CCR2 gene variants, may participate in the pathogenesis of allergic phenotypes at least in the Caucasian population.

Introduction

Asthma, allergic rhinitis and atopic eczema/dermatitis syndrome belong to allergic diseases. Their development is known to be the result of interactions between genetic background of the affected subject and environmental factors (Sengler *et al.*, 2002). Increasing evidence suggests that MCP-1 (monocyte chemoattractant protein-1, also known as CCL2) and its haematopoietic cell receptor CC chemokine receptor 2 (CCR2) are involved in inflammatory disorders of the lungs (Chung, 2005). MCP-1 appears to play a significant role in asthma pathogenesis because of its ability to attract eosinophils and monocytes, activate basophils and mast cells, inducing leucotriene C₄ release into the airway, which induces airway hyperresponsiveness (Campbell *et al.*, 1999). MCP-1 can also drive undifferentiated T-lymphocytes towards interleukin-14 (IL-4)-producing Th₂ cells (Karpus *et al.*, 1997) and thus be important in allergic inflammation. Furthermore, increased MCP-1 expression has been demonstrated in the bronchial epithelium of asthmatics (Sousa *et al.*, 1994). The coding gene for MCP-1 is located on chromosome 17q11.2, and gene for its receptor CCR2 lies on chromosome 3p21.3, regions for which linkage to asthma

or atopy has been demonstrated (Bu *et al.*, 2006; Steinke *et al.*, 2008). A single nucleotide polymorphism of the MCP-1 gene in the gene regulatory region was found to be related to the expression of MCP-1 (Rovin *et al.*, 1999). In addition, a substitution mutation (replacement of valine by isoleucine in the transmembrane region) has been described in the CCR2 gene (CCR2-64I). Given the importance of the chemokines and their receptors in the pathogenesis of allergic diseases, the aim of our study was to test whether allergic diseases or possibly related phenotypes are associated with selected polymorphisms in the MCP-1 and CCR2 genes in the Czech population.

Materials and methods

Subjects

This case-control study comprised 638 unrelated Czech subjects living in the South Moravia region. A total of 332 patients with clinically manifested allergic diseases (176 men and 156 women, aged 33.6 ± 12.9 years (mean \pm SD) — only asthma (34), only rhinitis (40), asthma and rhinitis (135), asthma and dermatitis (18), rhinitis and dermatitis (9) and combination of all three manifestations (96)) were studied. Allergic asthma diagnosis was based on the criteria of GINA 2002 (Global Initiative for Asthma) which include the following symptoms: non-productive cough, wheezing, breathlessness, reversibility airways obstruction, and bronchial hyperactivity and diagnostic test for IgE-mediated allergy. Diagnosis of allergic rhinitis was based on coordination between a typical history of allergic symptoms which include watery secretion from nose, nasal obstruction, nasal mucosa itching and sneezing, that are reversible spontaneously or after therapy (according to the criteria of Allergic Rhinitis and its Impact on Asthma Initiative, Bousquet *et al.*, 2001) and diagnostic test for IgE-mediated allergy. The diagnosis of atopic dermatitis was defined according to the diagnostic criteria firstly described by Hanifin & Rajka (1980).

Atopy was defined as the presence of positive skin test reaction (≥ 3 mm greater than reaction to saline) to 1 or more of the common allergens (house dust mite, common mixed grass and tree pollens, mixed moulds, cat and dog dander, together with histamine and normal saline as a positive and a negative control, respectively) and/or raised specific serum IgE levels (> 0.35 kU L⁻¹ by AlaSTAT test,

* Department of Pathophysiology, Medical Faculty, Masaryk University, Brno, Czech Republic, and † Department of Immunology, Medical Faculty, Palacky University, Olomouc, Czech Republic

Received 11 July 2008; revised xx xxxx 2008; accepted 9 October 2008

Correspondence: Lydie Izakovicova Holla, MD, PhD, Department of Pathophysiology, Medical Faculty, Masaryk University, Kamenice 5, UKB pav. A18, 625 00 Brno, Czech Republic. Tel: +42 054 9494229; Fax: +42 054 9492330; E-mail: holla@med.muni.cz

Table 1. MCP-1 and CCR2 polymorphisms and their relationship to the disease status, skin prick tests to selected allergens and/or body mass index

| a | | | | | | |
|--------------------------------------|--------|--|----------------------|----------------------|---------|------------------|
| MCP-1 –2518A/G (rs 1024611) | | Allele A, forward: 5'-GTGGGAGGCAGACAGCTA-3' Allele G, forward: 5'-GTGGGAGGCAGACAGCTG-3' Constant reverse: 5'-TGAGTGTTCACATAGGCTTC-3' | | | | |
| MCP-1 –2076A/T (rs 1024610) | | Allele A, forward: 5'-CATGGTAAAGGATGCACTAACA-3' Allele T, forward: 5'-CATGGTAAAGGATGCACTAACT-3' Constant reverse: 5'-GTCTCAGTCCTCTGCTCA-3' | | | | |
| b | | | | | | |
| Locus | Allele | Genotype | Patients (%) n = 332 | Controls (%) n = 306 | P value | OR (95% CI) |
| MCP-1 –2518 | A/G | AA | 56.0 | 57.5 | NS | 1.00 |
| | | AG | 39.2 | 34.3 | | 0.85 (0.61–1.19) |
| | | GG | 4.8 | 8.2 | | 1.65 (0.85–3.20) |
| MCP-1 –2076 | A/T | AA | 68.9 | 64.4 | NS | 1.00 |
| | | AT | 29.2 | 32.0 | | 1.14 (0.81–1.60) |
| | | TT | 3.9 | 3.6 | | 0.95 (0.42–2.18) |
| CCR2 Ile64Val | A/G | Ile/Ile (AA) | 1.3 | 2.0 | NS | 1.60 (0.44–5.73) |
| | | Ile/Val (AG) | 23.5 | 21.2 | | 0.89 (0.61–1.29) |
| | | Val/Val (GG) | 75.3 | 76.8 | | 1.00 |
| c | | | | | | |
| | | MCP-1 -2518 | | | | |
| Prick test — late spring mixture | | AA | AG | GG | P value | OR (95% CI) |
| % total (negative/positive tests) | | 53.1 (66.7/38.2) | 41.7 (28.3/56.4) | 5.2 (5.0/5.4) | 0.0020 | 3.24 (1.51–6.95) |
| d | | | | | | |
| | | CCR2Val64Ile | | | | |
| | | Ile/Ile | Ile/Val | Val/Val | P value | OR (95% CI) |
| Body mass index | | 24.9 ± 2.5 | 23.3 ± 5.0 | 21.8 ± 3.9 | 0.0069 | 1.70 (1.12–3.52) |

(a) Sequence-specific primers for both MCP-1 promoter polymorphisms.

(b) Genotype frequencies of MCP-1 and CCR2 polymorphisms in both groups (χ^2 test for genotype and Fisher exact test for allele frequencies were used; NS, non-significant).

(c) Results of the genetic data analysis in relation to the selected prick test (P value shows results of comparisons of numbers of subjects with negative (< 3 mm) versus positive (> 3 mm) prick test by Fisher exact test (odds ratio (OR) was calculated for AG + GG versus AA genotypes).

(d) Body mass index association with CCR2 polymorphism (by Kruskal–Wallis ANOVA, OR was calculated for Ile/Ile+Ile/Val versus Val/Val genotypes). CI, confidence interval.

DPC Biermann, Bad Nauheim, Germany; produced in response to one or more of the common allergens including *Dermatophagoides farinae*, grass pollens, animal danders and moulds) and/or raised total serum IgE levels above normal values (> 100 IU mL⁻¹ in non-smoking adults measured by the nephelometric test, Dade-Behring, Mannheim, Germany), as described previously (Holla *et al.*, 2002).

The control group consisted of 319 healthy subjects ($n = 306$, 161 men and 145 women, aged 41.5 ± 15.1 years) who met the following criteria: (i) no prior or current physician diagnosis of allergic diseases (rhinitis and/or asthma and/or dermatitis); (ii) no history of wheezing, shortness of breath and other symptoms of allergic diseases such as nasal and skin symptoms; (iii) no use of antiallergic

medications; and (iv) absence of first-degree relatives with a history of allergic diseases.

The study was approved by the Committee for Ethics of the Faculty of Medicine, Masaryk University, and informed consent was obtained from all participants, in line with the Helsinki declaration before inclusion in the study.

Genotyping

After DNA extraction, the MCP-1 –2518A/G and –2076A/T alleles were typed using polymerase chain reaction with sequence specific primers (PCR-SSCP, Table 1a), and Val64Ile (G190A) polymorphism of the CCR-2 was investigated by a PCR-RFLP method as described earlier (Munerato *et al.*, 2003).

Statistical analysis

We calculated allele frequencies and tested agreement with Hardy–Weinberg equilibrium using a χ^2 goodness-of-fit test. We then compared differences in the allele frequencies and genotype distribution of the polymorphisms between case and control subjects using Fisher exact and χ^2 test. Where appropriate, Bonferroni correction was applied to adjust the α level according to the number of independent comparisons to an overall value of 0.05. Adjusted P -values are denoted as P_{corr} ; $P_{\text{corr}} < 0.05$ was considered significant. The Kruskal–Wallis ANOVA test was used for the evaluation of total IgE levels and body mass index (BMI). Contingency table analysis, odds ratio (OR), 95% confidence intervals and significance values were estimated with the program package STATISTICA version 6.0 (Statsoft Inc., Tulsa, OK, USA).

Results and discussion

We found no association between any of the three investigated polymorphisms in the MCP-1 and CCR2 genes and clinical manifestation of allergic diseases ($P > 0.05$ in all cases, Table 1b). In allergic subjects, there were no relationships among CCR2 variant and a number of quantitative traits investigated in our study, including total serum IgE levels, selected specific IgE levels and skin test responses to aeroallergens (data not shown). However, this polymorphism was significantly associated with body mass index (BMI, $P = 0.007$, Kruskal–Wallis ANOVA, Table 1d). In contrast, both polymorphisms in MCP-1 promoter were related to skin prick test positivity to autumnal pollens ($P = 0.04$ for $-2518A/G$ and $P = 0.02$ for $-2076A/T$, data not shown) and $-2518G$ allele was significantly associated with sensitisation to late spring pollens (33.6% subjects with positive test versus 19.2% subjects with negative test, $P = 0.002$ by Fisher exact test, $P_{\text{corr}} < 0.05$, OR = 3.24, 95%CI: 1.51–6.95, Table 1c), but not with IgE levels or severity of asthma (data not shown).

MCP-1, one of the CC chemokines, appears to play a significant role in asthma pathogenesis because of its ability to attract eosinophils, monocytes, and activate mast cells and basophils. It can also drive T-lymphocytes towards IL-4-producing Th-2 type cells (Karpus *et al.*, 1997). A biallelic A/G polymorphism in the distal regulatory region at position -2518 has been found to affect the level of MCP-1 expression in response to inflammatory stimuli (Rovin *et al.*, 1999). Monocytes from individuals carrying a G allele at -2518 produce more MCP-1 after treatment with IL-1 β than monocytes from AA homozygotes. The effect of the G allele appears to be dose-dependent; cells from individuals homozygous for G allele at -2518 produce more MCP-1 than cells from G/A heterozygotes (Rovin *et al.*, 1999). The $-2518G$ allele increases susceptibility to asthma, asthma severity and eosinophil levels in Caucasians (Szalai *et al.*, 2001), but not in Chinese children (Yao *et al.*, 2004). In our study, the same allele was associated with allergen sensitisation to pollens. However, in contrast to both previous studies

that described significant associations of Val64Ile polymorphism in the CCR2 gene with allergic asthma in Koreans (Kim *et al.*, 2007) and with cedar pollinosis in Japanese (Nakamura *et al.*, 2007), we found no relationship of identical variant with clinically manifested allergic diseases or related phenotypes in Caucasians. In conclusion, our study supports the idea that MCP-1, but not CCR2 gene variants, may participate in the pathogenesis of particular allergic phenotypes at least in the Czech population. However, the functional relationship of ascertained associations still needs clarification. Thus, further genetic and functional studies are needed to elucidate the role of MCP-1 polymorphisms in the molecular mechanisms underlying.

Acknowledgements

This work was supported by the grant 310/06/0827 of the Czech Science Foundation.

References

- Bousquet, J., Van Cauwenberge, P.N. & Khaltaev, N. (2001) Allergic rhinitis and its impact on asthma: ARIA workshop report. *The Journal of Allergy and Clinical Immunology*, **108**(5 Suppl.), S147.
- Bu, L.M., Bradley, M., Söderhäll, C., Wahlgren, C.F., Kockum, I. & Nordenskjöld, M. (2006) Genome-wide linkage analysis of allergic rhinoconjunctivitis in a Swedish population. *Clinical and Experimental Allergy*, **36**, 204.
- Campbell, E.M., Charo, I.F., Kunkel, S.L., Strieter, R.M., Boring, L., Gosling, J. *et al.* (1999) Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2 $-/-$ mice: the role of mast cells. *Journal of Immunology*, **163**, 2160.
- Chung, K.F. (2005) Inflammatory mediators in chronic obstructive pulmonary disease. *Current Drug Targets Inflammation and Allergy*, **4**, 619.
- GINA (2002) Global Strategy for Asthma Management and Prevention. Global initiative for asthma. NIH Publication No. 01–3659, NHLBI/WHO (2002).
- Hanifin, J.M. & Rajka, G. (1980) Diagnostic features of atopic dermatitis. *Acta dermatologica venerologica Stockh*, **92**, 44.
- Holla, L.I., Buckova, D., Kuhrova, V., Stejskalova, A., Francova, H., Znojil, V. *et al.* (2002) Prevalence of endothelial nitric oxide synthase gene polymorphisms in patients with atopic asthma. *Clinical and Experimental Allergy*, **32**, 1193.
- Karpus, W.J., Lukacs, N.W., Kennedy, K.J. & Smith, W.S. (1997) Differential CC chemokine-induced enhancement of T helper cell cytokine production. *The Journal of Immunology*, **158**, 4129.
- Kim, Y.K., Oh, H.B., Lee, E.Y., Gho, Y.S., Lee, J.E. & Kim, Y.Y. (2007) Association between a genetic variation of CC chemokine receptor-2 and atopic asthma. *Allergy*, **62**, 208.
- Munerato, P., Azevedo, M.L., Sucupira, M.C.A., Pardini, R., Pinto, G.H.N., Catroxo, M. *et al.* (2003) Frequency of polymorphisms of genes coding for HIV-1 co-receptors CCR5 and CCR2 in a Brazilian population. *The Brazilian Journal of Infectious Diseases*, **7**, 236.
- Nakamura, H., Higashikawa, F., Nobukuni, Y., Miyagawa, K., Endo, T., Imai, T. *et al.* (2007) Genotypes and haplotypes of CCR2 and CCR3 genes in Japanese cedar pollinosis. *International Archives of Allergy Immunology*, **142**, 329.
- Rovin, B.H., Lu, L. & Saxena, R. (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1

- 1 expression. *Biochemical and Biophysical Research*
2 *Communications*, 259, 344.
- 3 Sengler, C., Lau, S., Wahn, U. & Nickel, R. (2002) Interaction
4 between genes and environmental factors in asthma and atopy:
5 new developments. *Respiratory Research*, 3, 7.
- 6 Sousa, A.R., Lane, S.J., Nakhosteen, J.A., Yoshimura, T., Lee, T.H.
7 & Poston, R.N. (1994) Increased expression of the monocyte
8 chemoattractant protein-1 in bronchial tissue from asthmatic
9 subjects. *American Journal of Respiratory Cell and Molecular*
10 *Biology*, 10, 142.
- 11 Steinke, J.W., Rich, S.S. & Borish, L. (2008) 5. Genetics of allergic
12 disease. *The Journal of Allergy and Clinical Immunology*,
13 121(2 Suppl.), S384.
- 14 Szalai, C., Kozma, G.T., Nagy, A., Bojszko, A., Krikovszky, D.,
15 Szabo, T. *et al.* (2001) Polymorphism in the gene regulatory
16 region of MCP-1 is associated with asthma susceptibility and
17 severity. *The Journal of Allergy and Clinical Immunology*, 108,
18 375.
- 19 Yao, T.C., Wu, K.C., Chung, H.T., Shaw, C.K., Kuo, M.L., Wu, C.J.
20 *et al.* (2004) MCP-1 gene regulatory region polymorphism in
21 Chinese children with mild, moderate and near-fatal asthma.
22 *Allergy*, 59, 436.
- 23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

Author Query Form

Journal: International Journal of Immunogenetics

Article: eji_816.fm

Dear Author,

During the copy-editing of your paper, the following queries arose. Please respond to these by marking up your proofs with the necessary changes/additions. Please write your answers on the query sheet if there is insufficient space on the page proofs. Please write clearly and follow the conventions shown on the attached corrections sheet. If returning the proof by fax do not write too close to the paper's edge. Please remember that illegible mark-ups may delay publication.

Many thanks for your assistance.

| No. | Query | Remarks |
|-----|---|---------|
| 1 | Wiley-Blackwell: Please supply revision date for this manuscript. | |
| 2 | Author: Please supply a short title for the paper, preferably not more than 30 characters including spaces. | |
| 3 | Author: Please confirm if its okay to use GINA 2002 as institutional author (to match with the citation in the text). | |

MARKED PROOF

Please correct and return this set

Please use the proof correction marks shown below for all alterations and corrections. If you wish to return your proof by fax you should ensure that all amendments are written clearly in dark ink and are made well within the page margins.

| <i>Instruction to printer</i> | <i>Textual mark</i> | <i>Marginal mark</i> |
|--|---|---|
| Leave unchanged | ... under matter to remain | Ⓟ |
| Insert in text the matter indicated in the margin | ∧ | New matter followed by ∧ or ∧ [Ⓢ] |
| Delete | / through single character, rule or underline or ┌───┐ through all characters to be deleted | Ⓞ or Ⓞ [Ⓢ] |
| Substitute character or substitute part of one or more word(s) | / through letter or ┌───┐ through characters | new character / or new characters / |
| Change to italics | — under matter to be changed | ↙ |
| Change to capitals | ≡ under matter to be changed | ≡ |
| Change to small capitals | ≡ under matter to be changed | ≡ |
| Change to bold type | ~ under matter to be changed | ~ |
| Change to bold italic | ≈ under matter to be changed | ≈ |
| Change to lower case | Encircle matter to be changed | ≡ |
| Change italic to upright type | (As above) | ⊕ |
| Change bold to non-bold type | (As above) | ⊖ |
| Insert 'superior' character | / through character or ∧ where required | Υ or Υ under character e.g. Υ or Υ |
| Insert 'inferior' character | (As above) | ∧ over character e.g. ∧ |
| Insert full stop | (As above) | ⊙ |
| Insert comma | (As above) | , |
| Insert single quotation marks | (As above) | ʹ or ʸ and/or ʹ or ʸ |
| Insert double quotation marks | (As above) | “ or ” and/or ” or ” |
| Insert hyphen | (As above) | ⊥ |
| Start new paragraph | ┌ | ┌ |
| No new paragraph | ┐ | ┐ |
| Transpose | └┐ | └┐ |
| Close up | linking ○ characters | ○ |
| Insert or substitute space between characters or words | / through character or ∧ where required | Υ |
| Reduce space between characters or words | | ↑ |